NRP104: Phase III data

In a placebo-controlled Phase III trial in 285 ADHD pediatric patients aged 6 to 12 years, all 3 doses of NRP104 met the primary and secondary endpoints on ADHD-RS and CPRS scores, respectively (p<0.0...